Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Kyle Connors
A Look At Drug Price Negotiation Program's Ongoing Impact
By David McIntosh, Margaux Hall and Kyle Connors ( February 10, 2025, 6:38 PM EST) -- More than two years after the passage of the Inflation Reduction Act[1] and the Centers for Medicare & Medicaid Services' rapid implementation of the drug price negotiation program,[2] the life sciences industry is adapting.... Law360 is on it, so you are, too. A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence.
A Look At Drug Price Negotiation Program's Ongoing Impact
Hello! I'm Law360's automated support bot. How can I help you today? For example, you can type: I forgot my password I took a free trial but didn't get a verification email How do I sign up for a newsletter?
Adapting To The IRA: Early Lessons Learned On The IRA's Impact On Deal-Making, Drug Economics, And Business Strategy
More than two years after the passage of the Inflation Reduction Act ("IRA")1 and the Centers for Medicare and Medicaid Services' ("CMS'") rapid implementation of the drug price negotiation program,2 the life sciences industry is adapting to new economic realities. Stakeholders are adjusting their corporate and regulatory strategies, and licensing transactions are increasingly incorporating contractual provisions to address the unpredictable economic impacts of the IRA's negotiation program.
Adapting to the IRA: Early Lessons Learned on the IRA’s Impact on Deal-Making, Drug Economics, and Business Strategy | JD Supra
More than two years after the passage of the Inflation Reduction Act (“IRA”)1 and the Centers for Medicare and Medicaid Services’ (“CMS’”) rapid implementation of the drug price negotiation program,2 the life sciences industry is adapting to new economic realities. Stakeholders are adjusting their corporate and regulatory strategies, and licensing transactions are increasingly incorporating contractual provisions to address the unpredictable economic impacts of the IRA’s negotiation program.
Continued Agency Strides Towards IRA Negotiation Program Implementation: CMS Issues Final Guidance on the 2026 Inflation Reduction Act Medicare Part D Negotiation Process
I. Introduction On June 30, 2023, the Centers for Medicare & Medicaid Services (“CMS”) issued its final guidance memorandum1 (the “Final Guidance”) on the implementation of the Inflation Reduction Act (“IRA”) Medicare Drug Price Negotiation Program for the Initial Price Applicability Year of 2026 (the “Initial Year”).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Kyle
Contact Kyle, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack